Aromatic Diamidine Analogs for Oral Anticancer Use With Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pentamidine, despite its antiprotozoal and antifungal efficacy, suffers from significant toxic side effects and poor oral bioavailability, limiting its use as an effective anticancer drug, particularly due to liver damage and central nervous system adverse events.
Innovation Solution
Development of aromatic diamidine analogs with enhanced pharmacokinetics and pharmacodynamics, offering increased cytotoxicity against cancer cells and improved oral bioavailability, reducing toxicity and enhancing liver targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If pentamidine is used as an anticancer drug, then cytotoxicity against cancer cells is achieved, but toxic side effects including liver damage and central nervous system adverse events occur
Solution Approach 1:
The patent modifies the chemical structure of pentamidine by changing parameters such as the length of the alkyl chain (n value in formulas I-IV), the aromatic ring substituents (R1-R8 groups), and the positions of amidine groups. These parameter changes result in analogs with improved therapeutic indices that maintain cytotoxicity against cancer cells while reducing toxic side effects including liver damage and central nervous system adverse events
Solution Approach 2:
The patent creates composite aromatic diamidine structures combining different aromatic rings (phenyl, pyridinyl, pyrimidinyl, pyrazinyl), various substituent groups (halo, alkyl, cycloalkyl, aryl, heteroaryl, amino), and amidine moieties. These composite structures yield compounds with optimized pharmacological profiles that preserve anticancer activity while mitigating toxicity
2Ease of operation
If pentamidine is administered orally, then convenience of administration is improved, but oral bioavailability remains poor
Solution Approach 1:
The patent optimizes molecular parameters of pentamidine analogs including aromatic ring systems, substituent types and positions, and chain lengths to enhance oral bioavailability. These parameter changes improve the compounds' ability to be absorbed orally while maintaining their cytotoxic activity against cancer cells
3Quantity of substance
If dose is increased for anticancer treatment, then therapeutic efficacy is improved, but toxic side effects are exacerbated
Solution Approach 1:
The patent develops pentamidine analogs with modified chemical parameters (aromatic ring substitutions, chain lengths, amidine positions) that achieve enhanced therapeutic efficacy at lower doses. The improved compounds exhibit better selectivity for cancer cells, allowing effective treatment at reduced dosages that minimize toxic side effects
Data Source
AI summary
The present disclosure provides a group of aromatic (e.g., pyridinyl, pyrimidinyl, pyrazinyl, or phenyl) diamidine analogs and pharmaceutically acceptable salts that are useful for treating a proliferative disease. The proliferative disease may include solid cancer or blood cancer. Compositions, methods of synthesizing the same and methods for treating various cancer using the analogs are disclosed herein. The present disclosure also provides pharmaceutical formulations comprising at least one of the compounds with a pharmaceutically acceptable carrier, diluent or excipient therefor.